BioLineRx Ltd. (BLRX) stock
BLRXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 20-F on Mar 23, 2026Score 3/30
$1.12−0.03 (-2.61%)
Close on Nov 17, 2026Market cap $4.87MP/E –Yield –
BioLineRx total assets
Total assets on the balance sheet at the end of each period.
BioLineRx's total assets was $33.48M at Jun 30, 2026. For fiscal 2025 it was $40.91M, up 5.1% from the year before. The highest annual figure on record is $81.39M in fiscal 2021.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $40.91M | +5.1% |
| FY2024 | Dec 31, 2024 | $38.91M | -39.1% |
| FY2023 | Dec 31, 2023 | $63.93M | -16.3% |
| FY2022 | Dec 31, 2022 | $76.38M | -6.2% |
| FY2021 | Dec 31, 2021 | $81.39M | +72.1% |
| FY2020 | Dec 31, 2020 | $47.29M | -11.7% |
| FY2019 | Dec 31, 2019 | $53.57M | -4.7% |
| FY2018 | Dec 31, 2018 | $56.23M | -7.8% |
| FY2017 | Dec 31, 2017 | $60.97M | +56.6% |
| FY2016 | Dec 31, 2016 | $38.94M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $33.48M | -48.2% |
| Q4 FY2025 | Dec 31, 2025 | $40.91M | -36.0% |
| Q2 FY2025 | Jun 30, 2025 | $43.27M | -26.6% |
| Q4 FY2024 | Dec 31, 2024 | $38.91M | -49.1% |
| Q2 FY2024 | Jun 30, 2024 | $64.60M | -4.8% |
| Q4 FY2023 | Dec 31, 2023 | $63.93M | -21.5% |
| Q2 FY2023 | Jun 30, 2023 | $58.94M | -35.5% |
| Q4 FY2022 | Dec 31, 2022 | $76.38M | +61.5% |
| Q2 FY2022 | Jun 30, 2022 | $67.84M | +28.0% |
| Q4 FY2021 | Dec 31, 2021 | $81.39M | +51.9% |
| Q2 FY2021 | Jun 30, 2021 | $91.33M | +47.4% |
| Q4 FY2020 | Dec 31, 2020 | $47.29M | -15.9% |
| Q2 FY2020 | Jun 30, 2020 | $52.99M | +1.5% |
| Q4 FY2019 | Dec 31, 2019 | $53.57M | -12.1% |
| Q2 FY2019 | Jun 30, 2019 | $61.96M | +59.1% |
| Q4 FY2018 | Dec 31, 2018 | $56.23M | – |
| Q2 FY2018 | Jun 30, 2018 | $52.21M | – |
| Q4 FY2017 | Dec 31, 2017 | $60.97M | – |
| Q4 FY2016 | Dec 31, 2016 | $38.94M | – |
See a number that looks wrong?